Pfizer OUT! Johnson, Johnson and Johnson, Roche may buy GSK

Pharmaceuticals, June 18 (Upi) -- Rumours have been swirling over the past few weeks that GlaxoSmithKline has been a target for Pfizer, but this time Uk-based traders are targeting another potential deal: the possibility of AerGe or Roche buying GSK, not Pfizerin a daily mail report, traders estimated that the average 1,900p a share would buy a large pharmaceutical companyThe single-share price could put GSK's total valuation at more than 92 billion euros ($143 billion), but GSK closed at 1,351 pence per share on MondayRumours of a takeoverhave been linked to the fall in GlaxoSmithKline's share price, which in mid-April was 1,642p and is now close to its January low of 1,327p, a far cry from the price of 1,700 per share two years agoa trader said people were being fooled by the priceThey have also been struck by a string of big dealspharmaceuticalcompanies, such as Actavis' brand was acquired by Allergan and a $22 billion asset swap deal between Glaxo and Novartisis it reasonable to say that GSK will be acquired by Johnson and Johnson or Roche? It may seem like the Johnson/Roche acquisition of GSK is not as eye-catching as Pfizer's acquisition of GSK, but in reality, GSK's joint venture with Novartis will help Johnson and Johnson's vastOTCand consumer businesses, and Johnson and Johnson is not involved in the vaccine business, which lacks respiratory products in its prescription drugs, which GSK has recently focused onMaybe Johnson and Johnson will be interested in this market? Well.....Maybelook at Roche, a Swiss drugmaker who has never been enthusiastic about a diversified market outside consumer care or diagnostics, but his fellow rival, Novartis, has long had a long track ahead of eye care, vaccines andover-the-counterRoche has focused on the diagnostic field, and its diagnostic department has even begun to develop targeted drugs using biomarkers and accompanying diagnostics Roche has been buying biotech companies since then, including last year's $8.3 billion acquisition of InterMune, in an effort to get as deep into the diagnostics field as possible the opposite of Pfizer, which already has a business of vaccines and consumer health care One banking analyst estimated the best price for a deal between Pfizer and GSK at 1,924p, higher than the current speculative price are not optimistic about Pfizer for too many reasons, and last year spent so much energy failing to fix AstraZeneca, as analysts say, perhaps a small acquisition like Shire or Perrigo would be a better option for GSK shareholders, the "strong union" is likely to be wishful thinking, CEO Andrew Witty's plan is to take it slow, but he would do well to compare the speed of his company's share price